Ongoing Task Force

Scientific perspective on in vivo DNT testing

Why

Discussions are ongoing regarding the integration of developmental neuroxocixity (DNT) testing in chemical safety assessment in Europe (e.g. via inclusion of DNT cohorts in EOGRT studies (OECD TG 443) or DNT (OECD TG 426) testing).

In addition, in vitro DNT tests are under development the outcome of which may trigger follow-up in vivo testing.

Therefore, there is a need to provide scientifically justifiable options and recommendations for integration of DNT testing in chemical risk assessments.

Objectives

  • Review options to amend/enhance existing paradigm (OECD 443 (additional DNT cohorts)/OECD 426)
  • Evaluate key DNT endpoints, incl. challenges in interpretation
  • Explore future integrated testing strategy, e.g. incorporating in vitro and current/future regulatory trend

Timeline and deliverables

Work started in February 2024 and the Task Force plans to have a manuscript ready for submission by the end of Q4 2024, beginning of Q5 2025.